![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 30, 2023
The Group is recognizing Dr. Forde as an exceptional physician-scientist who is making significant research contributions as a translational thoracic cancer investigator
February 10, 2023
Summaries of recently published ECOG-ACRIN research results
August 16, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
December 22, 2021
This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy
September 30, 2021
A new Language Guide provides guidelines on best practices with common phrases to use during presentations at medical conferences and within submitted abstracts
September 30, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
May 28, 2021
Dr. Lovly is the recipient of the 2021 ECOG-ACRIN Young Investigator Award, a highly prestigious recognition of research excellence
March 31, 2021
This phase III study, led by Drs. Patrick Forde and Anna Nowak, is evaluating durvalumab immunotherapy during and after standard chemotherapy versus chemotherapy alone
December 14, 2020
The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
December 14, 2020
Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction
June 10, 2020
This phase III trial is testing the antibody durvalumab added to standard chemoradiation followed by durvalumab for one year, compared to standard chemoradiation followed by one year of the antibody